Denali | Home
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative and lysosomal storage diseases …
Denali
We would like to show you a description here but the site won’t allow us.
Denali | Patient Community Engagement - Engage Parkinsons
Denali is committed to collaborating with the patient community as we aim to defeat degeneration. Our focus is on the individuals and families we are working to support. By actively engaging …
Denali | Defeat Degeneration
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Denali | Parkinson's Disease Clinical Program
Denali, in partnership with Biogen, is evaluating DNL151, also known as BIIB122, an investigational medication in pill form that may delay the progression of Parkinsons's disease …
today’s news •Interim results demonstrate average reduction of 64% (p < 0.001) from baseline in serum NfLafter 2 years of dosing with DNL310 in Phase 1/2 study
Denali | Frontotemporal Dementia (FTD) Clinical Program
Learn about Denali's Frontotemporal dementia (FTD) program. Frontotemporal dementia (FTD) associated with a mutation in the GRN (granulin) gene, referred to as FTD-GRN, is primarily …
Denali | Alzheimer's Disease Clinical Program
Denali is committed to working towards the discovery of potential treatments for Alzheimer’s disease, a progressive neurodegenerative disorder. Currently Denali’s pipeline has several …
Leadership - Denali
Success is accelerated by experience, collaboration and leadership. Denali’s Board of Directors combines expertise across industry, academia, drug development and the investment …
Denali has reported a greater than 90% mean reduction in CSF heparan sulfate at week 24 of treatment, remaining unchanged at week 104. Directly correlating the biomarker with clinical …